Symptom management.
O'Connor
Paul
P
Department of Medicine (Neurology), University of Toronto, Ontario, Canada.
D002186:Cannabinoids / Q000627:therapeutic use; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D009103:Multiple Sclerosis / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010276:Parasympatholytics / Q000627:therapeutic use; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology
D002186:Cannabinoids; D010276:Parasympatholytics